GSK and University of Oxford collaborate on a £50m project to research cancer prevention through vaccines targeting pre-cancerous cells. The aim is to leverage neoantigens to activate the immune system against cancer, with promising results seen in ongoing trials.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing